 | • レポートコード：MRC2312MG01630 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、61ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の血栓形成促進剤市場規模と予測を収録しています。・世界の血栓形成促進剤市場：売上、2018年-2023年、2024年-2029年 ・世界の血栓形成促進剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の血栓形成促進剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「ロミプロスチム」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 血栓形成促進剤のグローバル主要企業は、Amgen、 Kyowa Kirin、 Intas Pharmaceuticals、 SHIONOGI、 Novartis Pharma、 AkaRx、 Rigel Pharmaceuticals、 Kissei Pharmaceutical、 Grifols、 JW Pharmaceutical Corporation、 Medison Pharma Canada、 AstraZenecaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、血栓形成促進剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の血栓形成促進剤市場：タイプ別、2018年-2023年、2024年-2029年 世界の血栓形成促進剤市場：タイプ別市場シェア、2022年 ・ロミプロスチム、フォスタマチニブ、マルプレタ、ドプテレット、その他 世界の血栓形成促進剤市場：用途別、2018年-2023年、2024年-2029年 世界の血栓形成促進剤市場：用途別市場シェア、2022年 ・成人、小児 世界の血栓形成促進剤市場：地域・国別、2018年-2023年、2024年-2029年 世界の血栓形成促進剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における血栓形成促進剤のグローバル売上、2018年-2023年 ・主要企業における血栓形成促進剤のグローバル売上シェア、2022年 ・主要企業における血栓形成促進剤のグローバル販売量、2018年-2023年 ・主要企業における血栓形成促進剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Amgen、 Kyowa Kirin、 Intas Pharmaceuticals、 SHIONOGI、 Novartis Pharma、 AkaRx、 Rigel Pharmaceuticals、 Kissei Pharmaceutical、 Grifols、 JW Pharmaceutical Corporation、 Medison Pharma Canada、 AstraZeneca ************************************************************* ・調査・分析レポートの概要 血栓形成促進剤市場の定義 市場セグメント 世界の血栓形成促進剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の血栓形成促進剤市場規模 世界の血栓形成促進剤市場規模：2022年 VS 2029年 世界の血栓形成促進剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの血栓形成促進剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の血栓形成促進剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：ロミプロスチム、フォスタマチニブ、マルプレタ、ドプテレット、その他 血栓形成促進剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：成人、小児 血栓形成促進剤の用途別グローバル売上・予測 ・地域別市場分析 地域別血栓形成促進剤市場規模 2022年と2029年 地域別血栓形成促進剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Amgen、 Kyowa Kirin、 Intas Pharmaceuticals、 SHIONOGI、 Novartis Pharma、 AkaRx、 Rigel Pharmaceuticals、 Kissei Pharmaceutical、 Grifols、 JW Pharmaceutical Corporation、 Medison Pharma Canada、 AstraZeneca ... |
This research report provides a comprehensive analysis of the Thrombopoiesis Stimulating Agents market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Thrombopoiesis Stimulating Agents market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Thrombopoiesis Stimulating Agents, challenges faced by the industry, and potential opportunities for market players.
The global Thrombopoiesis Stimulating Agents market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Thrombopoiesis Stimulating Agents market presents opportunities for various stakeholders, including Adults, Pediatric Patients. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Thrombopoiesis Stimulating Agents market. Additionally, the growing consumer demand present avenues for market expansion.
The global Thrombopoiesis Stimulating Agents market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Thrombopoiesis Stimulating Agents market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Thrombopoiesis Stimulating Agents market.
Market Overview: The report provides a comprehensive overview of the Thrombopoiesis Stimulating Agents market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Romiplostim, Fostamatinib), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Thrombopoiesis Stimulating Agents market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Thrombopoiesis Stimulating Agents market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Thrombopoiesis Stimulating Agents market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Thrombopoiesis Stimulating Agents market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Thrombopoiesis Stimulating Agents market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Thrombopoiesis Stimulating Agents market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Thrombopoiesis Stimulating Agents, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Thrombopoiesis Stimulating Agents market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Thrombopoiesis Stimulating Agents market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Romiplostim
Fostamatinib
Mulpleta
Doptelet
Others
Market segment by Application
Adults
Pediatric Patients
Global Thrombopoiesis Stimulating Agents Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Amgen
Kyowa Kirin
Intas Pharmaceuticals
SHIONOGI
Novartis Pharma
AkaRx
Rigel Pharmaceuticals
Kissei Pharmaceutical
Grifols
JW Pharmaceutical Corporation
Medison Pharma Canada
AstraZeneca
Outline of Major Chapters:
Chapter 1: Introduces the definition of Thrombopoiesis Stimulating Agents, market overview.
Chapter 2: Global Thrombopoiesis Stimulating Agents market size in revenue.
Chapter 3: Detailed analysis of Thrombopoiesis Stimulating Agents company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Thrombopoiesis Stimulating Agents in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Thrombopoiesis Stimulating Agents Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Thrombopoiesis Stimulating Agents Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Thrombopoiesis Stimulating Agents Overall Market Size
2.1 Global Thrombopoiesis Stimulating Agents Market Size: 2022 VS 2029
2.2 Global Thrombopoiesis Stimulating Agents Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Thrombopoiesis Stimulating Agents Players in Global Market
3.2 Top Global Thrombopoiesis Stimulating Agents Companies Ranked by Revenue
3.3 Global Thrombopoiesis Stimulating Agents Revenue by Companies
3.4 Top 3 and Top 5 Thrombopoiesis Stimulating Agents Companies in Global Market, by Revenue in 2022
3.5 Global Companies Thrombopoiesis Stimulating Agents Product Type
3.6 Tier 1, Tier 2 and Tier 3 Thrombopoiesis Stimulating Agents Players in Global Market
3.6.1 List of Global Tier 1 Thrombopoiesis Stimulating Agents Companies
3.6.2 List of Global Tier 2 and Tier 3 Thrombopoiesis Stimulating Agents Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Thrombopoiesis Stimulating Agents Market Size Markets, 2022 & 2029
4.1.2 Romiplostim
4.1.3 Fostamatinib
4.1.4 Mulpleta
4.1.5 Doptelet
4.1.6 Others
4.2 By Type – Global Thrombopoiesis Stimulating Agents Revenue & Forecasts
4.2.1 By Type – Global Thrombopoiesis Stimulating Agents Revenue, 2018-2023
4.2.2 By Type – Global Thrombopoiesis Stimulating Agents Revenue, 2024-2029
4.2.3 By Type – Global Thrombopoiesis Stimulating Agents Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Thrombopoiesis Stimulating Agents Market Size, 2022 & 2029
5.1.2 Adults
5.1.3 Pediatric Patients
5.2 By Application – Global Thrombopoiesis Stimulating Agents Revenue & Forecasts
5.2.1 By Application – Global Thrombopoiesis Stimulating Agents Revenue, 2018-2023
5.2.2 By Application – Global Thrombopoiesis Stimulating Agents Revenue, 2024-2029
5.2.3 By Application – Global Thrombopoiesis Stimulating Agents Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Thrombopoiesis Stimulating Agents Market Size, 2022 & 2029
6.2 By Region – Global Thrombopoiesis Stimulating Agents Revenue & Forecasts
6.2.1 By Region – Global Thrombopoiesis Stimulating Agents Revenue, 2018-2023
6.2.2 By Region – Global Thrombopoiesis Stimulating Agents Revenue, 2024-2029
6.2.3 By Region – Global Thrombopoiesis Stimulating Agents Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Thrombopoiesis Stimulating Agents Revenue, 2018-2029
6.3.2 US Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.3.3 Canada Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.3.4 Mexico Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Thrombopoiesis Stimulating Agents Revenue, 2018-2029
6.4.2 Germany Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.4.3 France Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.4.4 U.K. Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.4.5 Italy Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.4.6 Russia Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.4.7 Nordic Countries Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.4.8 Benelux Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Thrombopoiesis Stimulating Agents Revenue, 2018-2029
6.5.2 China Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.5.3 Japan Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.5.4 South Korea Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.5.5 Southeast Asia Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.5.6 India Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Thrombopoiesis Stimulating Agents Revenue, 2018-2029
6.6.2 Brazil Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.6.3 Argentina Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Thrombopoiesis Stimulating Agents Revenue, 2018-2029
6.7.2 Turkey Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.7.3 Israel Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.7.4 Saudi Arabia Thrombopoiesis Stimulating Agents Market Size, 2018-2029
6.7.5 UAE Thrombopoiesis Stimulating Agents Market Size, 2018-2029
7 Thrombopoiesis Stimulating Agents Companies Profiles
7.1 Amgen
7.1.1 Amgen Company Summary
7.1.2 Amgen Business Overview
7.1.3 Amgen Thrombopoiesis Stimulating Agents Major Product Offerings
7.1.4 Amgen Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.1.5 Amgen Key News & Latest Developments
7.2 Kyowa Kirin
7.2.1 Kyowa Kirin Company Summary
7.2.2 Kyowa Kirin Business Overview
7.2.3 Kyowa Kirin Thrombopoiesis Stimulating Agents Major Product Offerings
7.2.4 Kyowa Kirin Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.2.5 Kyowa Kirin Key News & Latest Developments
7.3 Intas Pharmaceuticals
7.3.1 Intas Pharmaceuticals Company Summary
7.3.2 Intas Pharmaceuticals Business Overview
7.3.3 Intas Pharmaceuticals Thrombopoiesis Stimulating Agents Major Product Offerings
7.3.4 Intas Pharmaceuticals Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.3.5 Intas Pharmaceuticals Key News & Latest Developments
7.4 SHIONOGI
7.4.1 SHIONOGI Company Summary
7.4.2 SHIONOGI Business Overview
7.4.3 SHIONOGI Thrombopoiesis Stimulating Agents Major Product Offerings
7.4.4 SHIONOGI Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.4.5 SHIONOGI Key News & Latest Developments
7.5 Novartis Pharma
7.5.1 Novartis Pharma Company Summary
7.5.2 Novartis Pharma Business Overview
7.5.3 Novartis Pharma Thrombopoiesis Stimulating Agents Major Product Offerings
7.5.4 Novartis Pharma Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.5.5 Novartis Pharma Key News & Latest Developments
7.6 AkaRx
7.6.1 AkaRx Company Summary
7.6.2 AkaRx Business Overview
7.6.3 AkaRx Thrombopoiesis Stimulating Agents Major Product Offerings
7.6.4 AkaRx Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.6.5 AkaRx Key News & Latest Developments
7.7 Rigel Pharmaceuticals
7.7.1 Rigel Pharmaceuticals Company Summary
7.7.2 Rigel Pharmaceuticals Business Overview
7.7.3 Rigel Pharmaceuticals Thrombopoiesis Stimulating Agents Major Product Offerings
7.7.4 Rigel Pharmaceuticals Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.7.5 Rigel Pharmaceuticals Key News & Latest Developments
7.8 Kissei Pharmaceutical
7.8.1 Kissei Pharmaceutical Company Summary
7.8.2 Kissei Pharmaceutical Business Overview
7.8.3 Kissei Pharmaceutical Thrombopoiesis Stimulating Agents Major Product Offerings
7.8.4 Kissei Pharmaceutical Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.8.5 Kissei Pharmaceutical Key News & Latest Developments
7.9 Grifols
7.9.1 Grifols Company Summary
7.9.2 Grifols Business Overview
7.9.3 Grifols Thrombopoiesis Stimulating Agents Major Product Offerings
7.9.4 Grifols Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.9.5 Grifols Key News & Latest Developments
7.10 JW Pharmaceutical Corporation
7.10.1 JW Pharmaceutical Corporation Company Summary
7.10.2 JW Pharmaceutical Corporation Business Overview
7.10.3 JW Pharmaceutical Corporation Thrombopoiesis Stimulating Agents Major Product Offerings
7.10.4 JW Pharmaceutical Corporation Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.10.5 JW Pharmaceutical Corporation Key News & Latest Developments
7.11 Medison Pharma Canada
7.11.1 Medison Pharma Canada Company Summary
7.11.2 Medison Pharma Canada Business Overview
7.11.3 Medison Pharma Canada Thrombopoiesis Stimulating Agents Major Product Offerings
7.11.4 Medison Pharma Canada Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.11.5 Medison Pharma Canada Key News & Latest Developments
7.12 AstraZeneca
7.12.1 AstraZeneca Company Summary
7.12.2 AstraZeneca Business Overview
7.12.3 AstraZeneca Thrombopoiesis Stimulating Agents Major Product Offerings
7.12.4 AstraZeneca Thrombopoiesis Stimulating Agents Revenue in Global Market (2018-2023)
7.12.5 AstraZeneca Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer